Global Central Nervous System Therapeutics Market

Global Central Nervous System Therapeutics Market Size Insights Forecasts to 2035

• The Global Central Nervous System Therapeutics Market Size Was Estimated at USD 125.45 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.11% from 2025 to 2035
• The Worldwide Central Nervous System Therapeutics Market Size is Expected to Reach USD 295.84 Billion by 2035
• North America is expected to Grow the fastest during the forecast period.

According to a Research Report Published by Decisions Advisors and Consulting, The Global Central Nervous System Therapeutics Market Size was worth around USD 125.45 Billion in 2024 and is predicted to Grow to around USD 295.84 Billion by 2035 with a compound annual growth rate (CAGR) of 8.11% from 2025 to 2035. CNS disorders, especially neurodegenerative diseases like Parkinson's and Alzheimer's, are becoming more common as a result of this demographic transition. Moreover, older persons are increasingly prone to these illnesses, and there is an increasing need for treatment therapies that work, which presents profitable prospects for industry players.

 

Market Overview

The central nervous system (CNS) therapeutics market refers to the global industry focused on the research, development, production, and commercialisation of drugs and therapies that treat disorders affecting the brain, spinal cord, and peripheral nerves. Alzheimer's disease, Parkinson's disease, epilepsy, depression, schizophrenia, and brain tumours are among the ailments that these treatments treat. Gene treatments, biologics, small molecule medications, and regenerative techniques are examples of treatment modalities. The efficacy of these treatments has been improved by developments in drug delivery systems, such as the use of peripheral immune cells to breach the blood-brain barrier. This is due to an ageing population and a rise in neurological illnesses; the global market for CNS therapies is expanding significantly. More targeted and customised treatments are becoming possible thanks to advances in molecular biology, neurology, neuroimaging, genetic engineering, and precision medicine. New therapeutic approaches like gene therapy, stem cell therapy, and precision medicine have enormous potential to transform the treatment of CNS disorders while attracting significant funding and cooperation from biotech companies and academic institutions.

 

MapLight Therapeutics has raised $372.5 million in an oversubscribed Series D financing to advance its pipeline of central nervous system (CNS) therapeutics, including late-stage trials for its lead muscarinic agonist program targeting schizophrenia and Alzheimer’s psychosis.

 

Biogen's $165 million upfront deal with Stoke Therapeutics for Zorevunersens in Dravet syndrome, Sanofi's RNA partnership with Alloy, Lilly's AI-driven ALS antibody agreement with Alchemab, and a $230 million AI-gene therapy joint venture between Hologen and MeiraGTx targeting CNS disorders were among the notable alliances.

 

Report Coverage

This research report categorises the central nervous system therapeutics market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the central nervous system therapeutics market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the central nervous system therapeutics market.      

 

Driving Factors  

Globally, the need for improved therapies is being driven by an increase in the prevalence of disorders of the central nervous system. The global market for central nervous system therapies is anticipated to develop due to advancements in the diagnosis and treatment of illnesses of the central nervous system. The World Health Organisation estimates that approximately 1 billion people worldwide suffer from disorders of the central nervous system, including multiple sclerosis, Parkinson's disease, Alzheimer's disease, epilepsy, and stroke. Pharmaceutical companies have made significant investments in the discovery of innovative medicines to treat CNS illnesses due to the growing prevalence of these conditions. Numerous pertinent domains of technological progress are drawn to the CNS therapeutic market due to the increasing frequency of CNS disorders and the necessity for precise treatment and care. Modern medical care and precision-focused health technology have strengthened the business of the intelligent, bringing correct care and a beneficial influence on the market's difficult areas.

 

Globus Medical executed a $250 million acquisition of Nevro to extend its neuromodulation portfolio for chronic pain, and Lantheus paid $350 million up front to expand in CNS diagnostics.

 

Restraining Factors  

The intricacy of the brain and the stringent clinical trials required for safety and efficacy are the causes of the high development costs for CNS treatments, with strict FDA and EMA rules requiring additional data and monitoring, which slows down approvals that impact the market growth. Insufficient knowledge of the biology of the central nervous system (CNS) and the absence of distinct biomarkers for conditions such as schizophrenia, bipolar disorder, and Alzheimer's disease result in a high trial failure rate, which delays the market expansion.

 

Market Segmentation    

The central nervous system therapeutics market share is classified into drug class and distribution channel.     

• The CNS stimulants segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.        

Based on the drug class, the central nervous system therapeutics market is differentiated into anaesthetics, anticonvulsants, antiemetics, CNS stimulants, pain relievers, and others. Among these, the CNS stimulants segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The segment growth is supported by new drug approvals that increase treatment options, better diagnosis rates, and more awareness of mental health. Demand is also rising as sleep-related disorders like obstructive sleep apnea become more widely recognised. These elements, along with improved accessibility and physician preference for stimulant-based therapies, help explain their dominant market position.

• The hospital pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.      

Based on the application, the central nervous system therapeutics market is divided into hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.  Hospital pharmacies are preferred because of the requirement for quick access to medications, ongoing patient care, and efficient management of complicated patients. Hospital pharmacists are in a good position to satisfy the growing need for efficient therapeutic interventions as CNS illnesses become more common.

   

Regional Segment Analysis of the Central Nervous System Therapeutics Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is anticipated to hold the largest share of the central nervous system therapeutics market over the predicted timeframe.     

Asia Pacific is anticipated to hold the largest share of the central nervous system therapeutics market over the predicted timeframe. The main factors driving the market are the increasing government spending on healthcare infrastructure upgrades and the large number of people with unmet medical needs. Non-profit organisations are doing a fantastic job of raising awareness about mental health and CNS therapies while also offering free treatments for illnesses of the central nervous system. In 2024, China's central nervous system therapeutics market accounted for a significant portion of the Asia Pacific central nervous system therapeutics market due to an increase in neurological illnesses, especially Parkinson's disease.

 

North America is expected to grow at a rapid CAGR in the central nervous system therapeutics market during the forecast period. There is a tremendous demand for CNS therapies due to the rising incidence of neurodegenerative illnesses and other CNS diseases in the United States. Every year, brain cancer affects about 70,800 Americans, accounting for 2.4% of all cancer-related fatalities in the country. Furthermore, the growth of the market in this area is being greatly influenced by the existence of a number of major competitors and their increased investments in the creation of innovative treatments. Additionally, the market for central nervous system therapies has grown exponentially due to the rising public awareness of mental health issues and the availability of powerful pipeline drugs in North America.

 

Competitive Analysis:   

The report offers the appropriate analysis of the key organizations/companies involved within the central nervous system therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

 

List of Key Companies

• AstraZeneca
• Biogen
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Roche Holding AG (F. Hoffmann-La Roche Ltd.)
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd

• Others  

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• In October 2025, Plus Therapeutics provided an update on the commercial launch of its CNSide diagnostic platform, which is designed to detect and monitor central nervous system (CNS) cancers through cerebrospinal fluid (CSF) analysis. The company is expanding its commercial readiness, footprint, and leadership team to support rollout across the U.S.

 

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the central nervous system therapeutics market based on the below-mentioned segments: 

 

Global Central Nervous System Therapeutics Market, By Drug Class

• Anesthetics
• Anticonvulsants
• Antiemetics
• CNS Stimulants
• Pain Relievers
• Others

 

Global Central Nervous System Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

 

Global Central Nervous System Therapeutics Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What is the current size of the global CNS therapeutics market?

The market was valued at USD 125.45 billion in 2024.

 

2. What is the projected market size by 2035?

It is expected to reach USD 295.84 billion by 2035.

 

3. What is the forecasted CAGR for 2025-2035?

The market is projected to grow at a CAGR of 8.11%.

 

4. Which drug class holds the largest market share?

CNS stimulants accounted for the largest share in 2024 and are expected to grow significantly.

 

5. Which distribution channel dominates the market?

Hospital pharmacies generated the highest revenue in 2024 and are set for strong growth.

 

6. Which region is expected to grow the fastest?

North America is anticipated to grow at the fastest CAGR during the forecast period.

 

7. What drives growth in the Asia-Pacific region?

Factors include rising government healthcare spending, high unmet needs, and increasing neurological disorders like Parkinson's in countries such as China.